CAMBRIDGE, Mass., July 19, 2017 /PRNewswire/ -- Akcea Therapeutics,
Inc. today announced the closing of its initial public offering of
17,968,750 shares common stock at a public offering price of
$8.00 per share, including 2,343,750
shares of common stock issued upon full exercise by the
underwriters of their option to purchase additional shares.
The gross proceeds from the offering were $143.8 million before deducting underwriting
discounts and commissions and offering expenses to be paid by
Akcea. Akcea's common stock is listed on the NASDAQ Global
Select Market under the symbol "AKCA."
In addition, Novartis Pharma AG purchased $50.0 million of Akcea's common stock in a
separate private placement concurrent with the completion of
Akcea's initial public offering at a price per share equal to the
initial public offering price.
Cowen, Stifel and Wells Fargo Securities acted as joint book
running managers for the offering. BMO Capital Markets acted
as lead manager for the offering.
A registration statement relating to these securities has been
filed with the U.S. Securities and Exchange Commission and became
effective on July 13, 2017.
Copies of the registration statement can be accessed by visiting
the U.S. Securities and Exchange Commission website at
www.sec.gov.
The offering was made only by means of a prospectus. A
copy of the final prospectus relating to the offering was filed
with the U.S. Securities and Exchange Commission and may be
obtained from Cowen and Company, LLC, c/o Broadridge Financial
Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, or by telephone at (631) 274-2806; or from Stifel,
Nicolaus & Company, Incorporated, One
Montgomery Street, Suite 3700, San
Francisco, CA 94104, or by telephone at (415) 364-2720, or
by email at syndprospectus@stifel.com; or from Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, NY 10152, or by
telephone at (800) 326-5897, or by email at
cmclientsupport@wellsfargo.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
ABOUT AKCEA THERAPEUTICS
Akcea Therapeutics is a late-stage pharmaceutical company focused
on developing and commercializing drugs to treat patients with
serious cardiometabolic diseases caused by lipid disorders. Akcea
is advancing a mature pipeline of four novel drugs with the
potential to treat multiple diseases, including volanesorsen,
AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and
AKCEA-APOCIII-LRx, which are all based on antisense
technology developed by Ionis Pharmaceuticals, Inc. The most
advanced drug in its pipeline, volanesorsen, has successfully
completed a Phase 3 clinical program for the treatment of familial
chylomicronemia syndrome, or FCS, and is currently in Phase 3
clinical development for the treatment of familial partial
lipodystrophy, or FPL. Akcea is assembling the infrastructure to
commercialize its drugs globally with a focus on lipid specialists
as the primary call point. Akcea is a subsidiary of Ionis
Pharmaceuticals, Inc. and is located in Cambridge, Massachusetts.
In this press release, unless the context requires otherwise,
"Ionis", "Akcea," "Company," "Companies" "we," "our," and "us"
refers to Akcea Therapeutics and/or Ionis Pharmaceuticals.
Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals,
Inc. Ionis Pharmaceuticals™ is a trademark of Ionis
Pharmaceuticals, Inc.
View original content with
multimedia:http://www.prnewswire.com/news-releases/akcea-therapeutics-announces-closing-of-initial-public-offering-300490910.html
SOURCE Akcea Therapeutics, Inc.